
ALNAQ
Healthcare · Biotechnology · $122 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 5, 2024 | Time not confirmed | — | 0.00 | — |
| Nov 13, 2023 | After the close | 0.00 | 0.00 | — |
| Sep 22, 2023 | After the close | 0.00 | 0.00 | — |
| Jun 30, 2023 | After the close | 0.00 | 0.00 | — |
| Feb 24, 2023 | After the close | -0.05 | 0.00 | +100.0% |
| Nov 9, 2022 | Time not confirmed | -0.05 | 0.00 | +100.0% |
| Aug 15, 2022 | After the close | -0.07 | -0.08 | -14.3% |
| May 16, 2022 | After the close | -0.14 | -0.13 | +7.1% |
| Mar 31, 2022 | After the close | -0.16 | -0.11 | +31.3% |
| Nov 10, 2021 | After the close | -0.18 | -0.17 | +5.6% |
| Aug 10, 2021 | After the close | -0.21 | -0.24 | -14.3% |
| May 11, 2021 | Before the open | -0.23 | -0.21 | +8.7% |
| Mar 9, 2021 | Before the open | -0.19 | -0.24 | -26.3% |
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in…
| Nov 9, 2020 | Before the open | -0.21 | -0.22 | -4.8% |
| Aug 5, 2020 | Before the open | -0.27 | -0.26 | +3.7% |
| May 13, 2020 | Before the open | -0.45 | -0.31 | +31.1% |
| Mar 16, 2020 | Before the open | -0.53 | -0.47 | +11.3% |
| Nov 13, 2019 | Before the open | -0.49 | -0.57 | -16.3% |
| Aug 7, 2019 | Before the open | -0.54 | -0.54 | 0.0% |
| May 8, 2019 | Before the open | -0.49 | -0.55 | -12.2% |
| Mar 7, 2019 | Before the open | -0.51 | -0.46 | +9.8% |
| Nov 7, 2018 | Before the open | -0.47 | -0.46 | +2.1% |
| Aug 7, 2018 | Before the open | -0.40 | -0.42 | -5.0% |
| May 8, 2018 | Before the open | -0.42 | -0.38 | +9.5% |
| Mar 27, 2018 | Before the open | -0.55 | -0.48 | +12.7% |